Strategic process -- Formal engagement with Evercore concluded; current focus is on Phase III clinical execution, with ...

CRRT (Continuous Renal Replacement Therapy): A form of dialysis used for critically ill patients that continuously removes ...

Increased 5% with management citing ongoing focus on profitable accounts. Technology Platform Development -- Infusion of ...

Achieved additional $75 million in partnering proceeds from Sanofi and GileadGranted license to additional preclinical program to Gilead that leverages MacroGenics' novel T-cell engager platformRealig ...

Capital raised -- $17.1 million in new funding was secured, including a $13 million post-quarter investment from a leading ...

Q3 2025 Management View CEO Daniel O'Connell stated that "in the third quarter, we continued our track record of operational execution on 2 fronts: the steady progression of our Phase II ALTITUDE-AD ...

VANCOUVER, BC / ACCESS Newswire / November 11, 2025 / (TSX:NANO)(OTCQB:NNOMF)(Frankfurt:LBMB) Business Operational Highlights Newly installed proprietary agitator in full-scale One-Pot™ reactor at ...

Q3 2025 Earnings Call November 13, 2025 10:00 AM ESTCompany ParticipantsManuel Zuniga Pflucker - President, CEO & ...

Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS) Q3 2025 Earnings Call Transcript November 12, 2025 Acumen Pharmaceuticals, Inc.

Creative Realities, Inc. (NASDAQ: CREX) Q3 2025 Earnings Call Transcript November 12, 2025 Creative Realities, Inc. misses on ...

Key Data Highlighting Vidofludimus Calcium's Therapeutic Potential in Multiple Sclerosis Presented at 41st Congress of ECTRIMS  – – Phase 2 CALLIPER ...

Transportadora de Gas del Sur S.A. delivered a strong Q3 rebound, with profits up 63% Y/Y to AR$112M. Click here to read why ...